Strategic License Agreements - Narrative (Details) - USD ($)		1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 21, 2021	Sep. 30, 2021	Jul. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized				$ 0	$ 174,000	$ 886,000	$ 2,161,000
Deferred revenue				0		0		$ 2,696,000
Deferred revenue, current				0		0		517,000
Contract assets				0	0	0	0
License [Member] | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Full reimbursement of costs included in upfront fixed payment received	$ 1,800,000
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non refundable payment received	$ 21,500,000
Percentage of payment for cost incurred in trial	50.00%
Rate of revenue share	25.00%
Eligible reimbursement (up to)			$ 3,000,000
Upfront payment	$ 21,500,000
Estimated amount due as part of trial			3,600,000
Amount of related party transaction			25,100,000
Allocation for stand-alone selling prices			12,000,000
Deferred revenue				0		0		3,600,000
Deferred revenue, current								$ 2,400,000
Immedica Pharma AB | PEACE Trial and BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of modified transaction price			9,600,000
Revenue recognized					$ 200,000		$ 2,200,000
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of modified transaction price			$ 3,500,000
Immedica Pharma AB | License Agreements
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized		$ 12,000,000
Immedica Pharma AB | Peace Phase 3 Trial and Drug Supply
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized				$ 0		$ 900,000
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in trial	50.00%
Maximum amount of costs to reimburse	$ 1,800,000